Research programme: ubiquitin ligase inhibitors - Proteologics

Drug Profile

Research programme: ubiquitin ligase inhibitors - Proteologics

Alternative Names: Midline-1 inhibitor - Proteologics; PRT14-2; PRT3; PRT42; PRT44; TRIM 18 inhibitor - Proteologics

Latest Information Update: 21 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteologics
  • Developer GlaxoSmithKline; Proteologics; University of Newcastle, Australia
  • Class Small molecules
  • Mechanism of Action HIV replication inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma; Cancer
  • Discontinued HIV infections

Most Recent Events

  • 18 Mar 2013 Ubiquitin ligase inhibitors is still in preclinical trials for Cancer is Israel
  • 01 Mar 2013 Ubiquitin ligase inhibitors programme is available for licensing as of 01 Mar 2013. http://www.proteologics.com
  • 25 Feb 2013 Discontinued - Preclinical for HIV infections in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top